Cost-effectiveness analysis of community-led HIV self-testing among key populations in Côte d'Ivoire, Mali, and Senegal

IF 4.6 1区 医学 Q2 IMMUNOLOGY Journal of the International AIDS Society Pub Date : 2024-07-21 DOI:10.1002/jia2.26334
Ingrid Jiayin Lu, Romain Silhol, Marc d'Elbée, Marie-Claude Boily, Nirali Soni, Odette Ky-Zerbo, Anthony Vautier, Artlette Simo Fosto, Kéba Badiane, Metogara Traoré, Fern Terris-Prestholt, Joseph Larmarange, Mathieu Maheu-Giroux, for the ATLAS Team
{"title":"Cost-effectiveness analysis of community-led HIV self-testing among key populations in Côte d'Ivoire, Mali, and Senegal","authors":"Ingrid Jiayin Lu,&nbsp;Romain Silhol,&nbsp;Marc d'Elbée,&nbsp;Marie-Claude Boily,&nbsp;Nirali Soni,&nbsp;Odette Ky-Zerbo,&nbsp;Anthony Vautier,&nbsp;Artlette Simo Fosto,&nbsp;Kéba Badiane,&nbsp;Metogara Traoré,&nbsp;Fern Terris-Prestholt,&nbsp;Joseph Larmarange,&nbsp;Mathieu Maheu-Giroux,&nbsp;for the ATLAS Team","doi":"10.1002/jia2.26334","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>HIV self-testing (HIVST) is a promising strategy to improve diagnosis coverage among key populations (KP). The ATLAS (<i>Auto Test VIH, Libre d'Accéder à la connaissance de son Statut</i>) programme implemented HIVST in three West African countries, distributing over 380,000 kits up between 2019 and 2021, focussing on community-led distribution by KP to their peers and subsequent secondary distribution to their partners and clients. We aim to evaluate the cost-effectiveness of community-led HIVST in Côte d'Ivoire, Mali and Senegal.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>An HIV transmission dynamics model was adapted and calibrated to country-specific epidemiological data and used to predict the impact of HIVST. We considered the distribution of HIVST among two KP—female sex workers (FSW), and men who have sex with men (MSM)—and their sexual partners and clients. We compared the cost-effectiveness of two scenarios against a counterfactual without HIVST over a 20-year horizon (2019–2039). The ATLAS-only scenario mimicked the 2-year implemented ATLAS programme, whereas the ATLAS-scale-up scenario achieved 95% coverage of HIVST distribution among FSW and MSM by 2025 onwards. The primary outcome is the number of disability-adjusted life-years (DALY) averted. Scenarios were compared using incremental cost-effectiveness ratios (ICERs). Costing was performed using a healthcare provider's perspective. Costs were discounted at 4%, converted to $USD 2022 and estimated using a cost-function to accommodate economies of scale.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The ATLAS-only scenario was highly cost-effective over 20 years, even at low willingness-to-pay thresholds. The median ICERs were $126 ($88–$210) per DALY averted in Côte d'Ivoire, $92 ($88–$210) in Mali and 27$ ($88–$210) in Senegal. Scaling-up the ATLAS programme would also be cost-effective, and substantial epidemiological impacts would be achieved. The ICERs for the scale-up scenario were $199 ($122–$338) per DALY averted in Côte d'Ivoire, $224 ($118–$415) in Mali and $61 ($18–$128) in Senegal.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Both the implemented and the potential scale-up of community-led HIVST programmes in West Africa, where KP are important to overall transmission dynamics, have the potential to be highly cost-effective, as compared to a scenario without HIVST. These findings support the scale-up of community-led HIVST to reach populations that otherwise may not access conventional testing services.</p>\n </section>\n </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"27 7","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11260876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26334","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

HIV self-testing (HIVST) is a promising strategy to improve diagnosis coverage among key populations (KP). The ATLAS (Auto Test VIH, Libre d'Accéder à la connaissance de son Statut) programme implemented HIVST in three West African countries, distributing over 380,000 kits up between 2019 and 2021, focussing on community-led distribution by KP to their peers and subsequent secondary distribution to their partners and clients. We aim to evaluate the cost-effectiveness of community-led HIVST in Côte d'Ivoire, Mali and Senegal.

Methods

An HIV transmission dynamics model was adapted and calibrated to country-specific epidemiological data and used to predict the impact of HIVST. We considered the distribution of HIVST among two KP—female sex workers (FSW), and men who have sex with men (MSM)—and their sexual partners and clients. We compared the cost-effectiveness of two scenarios against a counterfactual without HIVST over a 20-year horizon (2019–2039). The ATLAS-only scenario mimicked the 2-year implemented ATLAS programme, whereas the ATLAS-scale-up scenario achieved 95% coverage of HIVST distribution among FSW and MSM by 2025 onwards. The primary outcome is the number of disability-adjusted life-years (DALY) averted. Scenarios were compared using incremental cost-effectiveness ratios (ICERs). Costing was performed using a healthcare provider's perspective. Costs were discounted at 4%, converted to $USD 2022 and estimated using a cost-function to accommodate economies of scale.

Results

The ATLAS-only scenario was highly cost-effective over 20 years, even at low willingness-to-pay thresholds. The median ICERs were $126 ($88–$210) per DALY averted in Côte d'Ivoire, $92 ($88–$210) in Mali and 27$ ($88–$210) in Senegal. Scaling-up the ATLAS programme would also be cost-effective, and substantial epidemiological impacts would be achieved. The ICERs for the scale-up scenario were $199 ($122–$338) per DALY averted in Côte d'Ivoire, $224 ($118–$415) in Mali and $61 ($18–$128) in Senegal.

Conclusions

Both the implemented and the potential scale-up of community-led HIVST programmes in West Africa, where KP are important to overall transmission dynamics, have the potential to be highly cost-effective, as compared to a scenario without HIVST. These findings support the scale-up of community-led HIVST to reach populations that otherwise may not access conventional testing services.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在科特迪瓦、马里和塞内加尔的重点人群中开展社区主导的艾滋病毒自我检测的成本效益分析。
导言:艾滋病毒自我检测(HIVST)是提高重点人群(KP)诊断覆盖率的一项有前途的策略。ATLAS (Auto Test VIH, Libre d'Accéder à la connaissance de son Statut) 计划在三个西非国家实施了 HIVST,在 2019 年至 2021 年期间发放了超过 38 万套试剂盒,重点是由社区主导,由关键人群向其同伴发放,随后再向其伴侣和客户二次发放。我们旨在评估科特迪瓦、马里和塞内加尔由社区主导的艾滋病毒检测的成本效益:我们根据具体国家的流行病学数据对艾滋病毒传播动态模型进行了调整和校准,并利用该模型预测艾滋病毒检测的影响。我们考虑了 HIVST 在两个主要群体--女性性工作者 (FSW) 和男男性行为者 (MSM) --及其性伴侣和客户中的分布情况。我们将两种方案的成本效益与 20 年内(2019-2039 年)不采用 HIVST 的反事实方案进行了比较。纯 ATLAS 方案模拟了实施 2 年的 ATLAS 计划,而 ATLAS 扩大方案则在 2025 年之前实现了在性工作者和 MSM 中 95% 的 HIVST 传播覆盖率。主要结果是避免残疾调整寿命年数(DALY)。采用增量成本效益比 (ICER) 对各种方案进行比较。成本计算从医疗服务提供者的角度进行。成本贴现率为 4%,转换为 2022 美元,并使用成本函数进行估算,以适应规模经济:结果:纯 ATLAS 方案在 20 年内具有很高的成本效益,即使在支付意愿阈值较低的情况下也是如此。在科特迪瓦,每减少 1 DALY 的 ICER 中位数为 126 美元(88 美元-210 美元),在马里为 92 美元(88 美元-210 美元),在塞内加尔为 27 美元(88 美元-210 美元)。扩大 ATLAS 计划的规模也将具有成本效益,并将产生重大的流行病学影响。在扩大规模的情况下,科特迪瓦每减少 1 DALY 的 ICER 为 199 美元(122-338 美元),马里为 224 美元(118-415 美元),塞内加尔为 61 美元(18-128 美元):与不开展艾滋病毒检测的情况相比,在西非实施和可能扩大由社区主导的艾滋病毒检测计划具有很高的成本效益。这些研究结果支持扩大社区主导的艾滋病毒检测范围,以覆盖那些可能无法获得常规检测服务的人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of the International AIDS Society
Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
8.60
自引率
10.00%
发文量
186
审稿时长
>12 weeks
期刊介绍: The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
期刊最新文献
In-utero exposure to tenofovir-containing pre-exposure prophylaxis and bone mineral content in HIV-unexposed infants in South Africa Patient and public involvement in HIV research: a mapping review and development of an online evidence map Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual Excess mortality attributable to AIDS among people living with HIV in high-income countries: a systematic review and meta-analysis Pre-exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross-sectional analysis in two communities in western Kenya, 2021–2023
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1